HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: 2342031996v1 234/2/625    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Di Stefano, D. R. Articles by Delpero, J.-R. Search for Related Content PubMed PubMed Citation Articles by Di Stefano, D. R. Articles by Delpero, J.-R.

Preoperative Percutaneous Portal Vein Embolization: Evaluation of Adverse Events in 188 Patients¹

¹ From the Institut Paoli Calmettes, Marseille, France (D.R.D.S., J.R.D.); Department of Interventional Radiology, Institut Gustave Roussy, 39 Rue Camilles Desmoulins, 94805 Villejuif, France (T.d.B., A.H., D.E.); Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (A.D., M.G.); Hôpital Saint André, Bordeaux, France (G.G., J.S., H.T.); and Centre Hospitalier Universitaire La Timone, Marseille, France (P.P., J.M.B.). Received December 9, 2003; revision requested February 16, 2004; revision received April 5; accepted April 22. Address correspondence to T.d.B. (e-mail: debaere@igr.fr).

PURPOSE: To retrospectively assess the frequency of adverse events related to percutaneous preoperative portal vein embolization (PPVE).

MATERIALS AND METHODS: Institutional review board did not require its approval or patient informed consent for this study. The adverse events that occurred during PPVE or until planned hepatic surgery was performed or cancelled were retrospectively obtained from clinical, imaging, and laboratory data files in 188 patients (109 male and 79 female patients; mean age, 60 years; range, 16–78 years). Liver resection was planned for metastases (n = 137), hepatocarcinoma (n = 31), cholangiocarcinoma (n = 15), fibrolamellar hepatoma (n = 1), and benign disease (n = 4). PPVE was performed with a single-lumen 5-F catheter and a contralateral approach with n-butyl cyanoacrylate mixed with iodized oil as the main embolic agent. The rate of complications in patients with cirrhosis was compared with that in patients without cirrhosis by using the ² test.

RESULTS: Adverse events occurred in 24 (12.8%) of 188 patients, including 12 complications and 12 incidental imaging findings. Complications included thrombosis of the portal vein feeding the future remnant liver (n = 1); migration of emboli in the portal vein feeding the future remnant liver, which necessitated angioplasty (n = 2); hemoperitoneum (n = 1); rupture of a metastasis in the gallbladder (n = 1); transitory hemobilia (n = 1); and transient liver failure (n = 6). Incidental findings were migration of small emboli in nontargeted portal branches (n = 10) and subcapsular hematoma (n = 2). Among the 187 patients in whom PPVE was technically successful, there was a significant difference (P < .001) between the occurrence of liver failure after PPVE in patients with cirrhosis (five of 30) and those without (one of 157). Sixteen liver resections were cancelled due to cancer progression (n = 12), insufficient hypertrophy of the nonembolized liver (n = 3), and complete portal thrombosis (n = 1).

CONCLUSION: PPVE is a safe adjuvant technique for hypertrophy of the initially insufficient liver reserve. Post-PPVE transient liver failure is more common in patients with cirrhosis than in those without cirrhosis.

© RSNA, 2004

This article has been cited by other articles:

				A. L. Denys, T. De Baere, and F. Doenz Portal vein embolization: a plea for strict patient selection. Am. J. Roentgenol., July 1, 2006; 187(1): W125 - W125. [Full Text] [PDF]